Assessment of Adherence to Atovaquone-Proguanil Prophylaxis in Travelers

被引：24

作者：

DePetrillo, John C. ^{[1
]}

Singer, Carol ^{[1
]}

Bergagnini, Isabella A. ^{[1
]}

Kolakowski, Patricia ^{[1
]}

Edwards, Barbara ^{[1
]}

Smith, Miriam A. ^{[1
,2
]}

机构：

[1] Long Isl Jewish Med Ctr, Div Infect Dis, Dept Med, New Hyde Pk, NY 11040 USA

[2] N Shore Univ Hosp, Dept Med, Forest Hills, NY USA

来源：

JOURNAL OF TRAVEL MEDICINE | 2010年 / 17卷 / 04期

关键词：

PLASMODIUM-FALCIPARUM MALARIA; DOUBLE-BLIND; CHLOROQUINE-PROGUANIL; NONIMMUNE TRAVELERS; PLUS PROGUANIL; UNITED-STATES; HALOFANTRINE; SURVEILLANCE; EFFICACY; CHILDREN;

D O I：

10.1111/j.1708-8305.2010.00426.x

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Methods. Men and non-pregnant women >= 18 years of age were eligible for inclusion. Enrolled travelers received a prescription for atovaquone-proguanil prophylaxis and were contacted by telephone within 3 weeks of return to the United States. A questionnaire was prepared by the authors to determine if subjects were adherent with the medication. Additional data included demographics, duration of malarious travel, previous use of prophylactic agents, underlying medical conditions, concurrent medications, and reasons for non-adherence. Results. Complete data were available for 104/124 (84%) participants: 49 (47%) men, 55 (53%) women. Average duration of malarious travel was 12 days, and 19 (18%) travelers reported previous travel to a malarious region. Ninety-two (89%) subjects were completely adherent with their prophylactic atovaquone-proguanil course. Adverse effects were seen in 6 (5%) travelers. Conclusions. Adherence with atovaquone-proguanil malaria prophylaxis is high among travelers from a non-endemic region. Adverse effects are minimal. Non-adherence was primarily attributable to travelers' perception of need.

引用

页码：217 / 220

页数：4

共 23 条

[1] Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children [J].

Anabwani, G ;

Canfield, CJ ;

Hutchinson, DBA .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (05) :456-461

[2]

Behrens R H, 1998, J Travel Med, V5, P92, DOI 10.1111/j.1708-8305.1998.tb00471.x

[3] Atovaquone-proguanil: Report from the CDC expert meeting on malaria chemoprophylaxis (II) [J].

Boggild, Andrea K. ;

Parise, Monica E. ;

Lewis, Linda S. ;

Kain, Kevin C. .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 76 (02) :208-223

[4]

Bouchaud O, 2000, AM J TROP MED HYG, V63, P274

[5] Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: Results of an international, randomized, open-label study [J].

Camus, D ;

Djossou, F ;

Schilthuis, HJ ;

Hogh, B ;

Dutoit, E ;

Malvy, D ;

Roskell, NS ;

Hedgley, C ;

De Boever, EH ;

Miller, GB .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1716-1723

[6]

Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P597

[7]

HELD TK, 1994, Q J MED, V87, P17

[8] The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America [J].

Hill, David R. ;

Ericsson, Charles D. ;

Pearson, Richard D. ;

Keystone, Jay S. ;

Freedman, David O. ;

Kozarsky, Phyllis E. ;

DuPont, Herbert L. ;

Bia, Frank J. ;

Fischer, Philip R. ;

Ryan, Edward T. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) :1499-1539

[9] Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers:: a randomised, double-blind study [J].

Hogh, B ;

Clarke, PD ;

Camus, D ;

Nothdurft, HD ;

Overbosch, D ;

Günther, M ;

Joubert, I ;

Kain, KC ;

Shaw, D ;

Roskell, NS ;

Chulay, JD .

LANCET, 2000, 356 (9245) :1888-1894

[10]

KOZARSKY PE, 2005, CTR DIS CONTROL PREV

← 1 2 3 →